CN110198943A - 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 - Google Patents

作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 Download PDF

Info

Publication number
CN110198943A
CN110198943A CN201880008008.9A CN201880008008A CN110198943A CN 110198943 A CN110198943 A CN 110198943A CN 201880008008 A CN201880008008 A CN 201880008008A CN 110198943 A CN110198943 A CN 110198943A
Authority
CN
China
Prior art keywords
compound
added
synthesis
solution
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880008008.9A
Other languages
English (en)
Other versions
CN110198943B (zh
Inventor
钱文远
杨纯道
李正伟
李婕
黎健
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuxi Zhikang Hongyi Biotechnology Co ltd
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN110198943A publication Critical patent/CN110198943A/zh
Application granted granted Critical
Publication of CN110198943B publication Critical patent/CN110198943B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

本发明公开了一类具有Wee1的抑制作用的1,2‑二氢‑3H‑吡唑[3,4‑d]嘧啶‑3‑酮类化合物，并包含这些化合物在治疗各类肿瘤方面的应用。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201880008008.9A 2017-01-23 2018-01-19 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物 Active CN110198943B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710058856 2017-01-23
CN2017100588568 2017-01-23
CN2017113767693 2017-12-19
CN201711376769 2017-12-19
PCT/CN2018/073360 WO2018133829A1 (zh) 2017-01-23 2018-01-19 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物

Publications (2)

Publication Number Publication Date
CN110198943A true CN110198943A (zh) 2019-09-03
CN110198943B CN110198943B (zh) 2021-04-16

Family

ID=62907769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880008008.9A Active CN110198943B (zh) 2017-01-23 2018-01-19 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物

Country Status (6)

Country Link
US (1) US10954253B2 (zh)
EP (1) EP3572413B1 (zh)
JP (1) JP6717457B2 (zh)
CN (1) CN110198943B (zh)
ES (1) ES2902050T3 (zh)
WO (1) WO2018133829A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591334A (zh) * 2020-12-04 2022-06-07 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
WO2024011883A1 (zh) * 2022-07-13 2024-01-18 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2019169065A2 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
JP7300460B2 (ja) 2018-03-09 2023-06-29 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン
EP3943496A4 (en) 2019-03-22 2022-05-18 Shouyao Holdings (Beijing) Co., Ltd. WEE1 INHIBITOR AND METHOD OF MANUFACTURE AND USE THEREOF
WO2020210375A1 (en) 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
MX2021015572A (es) * 2019-06-28 2022-04-06 Shanghai Pharmaceuticals Holding Co Ltd Compuesto de pirazolopirimidina, método de preparación para el mismo y sus aplicaciones.
CA3180664A1 (en) * 2020-06-17 2021-12-23 Yuli Xie Pyrazolo[3,4-d]pyrimidine-3-one derivative as wee-1 inhibitor
TW202322812A (zh) * 2021-11-01 2023-06-16 大陸商正大天晴藥業集團股份有限公司 吡唑［３，４－ｄ］嘧啶－３－酮類化合物、包含其的藥物組合物及其醫藥用途
CN116462687A (zh) 2022-01-18 2023-07-21 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途
CN115521309A (zh) * 2022-09-16 2022-12-27 思科(深圳)药物研发有限公司 一种依鲁奥克杂质及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432284A (zh) * 2006-04-27 2009-05-13 万有制药株式会社 二氢吡唑并嘧啶酮衍生物
EP2213673A4 (en) * 2007-10-23 2011-09-07 Msd Kk PYRIDONE-SUBSTITUTED DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE
CN105209463A (zh) * 2013-04-11 2015-12-30 阿尔麦克探索有限公司 2-氨基吡啶并[4,3-d]嘧啶-5-酮衍生物及其作为Wee-1抑制剂的用途
CN105829315A (zh) * 2013-12-19 2016-08-03 阿尔麦克探索有限公司 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155752B1 (en) 2007-04-25 2018-09-19 Merck Sharp & Dohme Corp. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
PT2477628E (pt) 2009-09-15 2014-11-25 Merck Sharp & Dohme Preparação de formas de hemihidrato cristalino de dihidropirazolopirimidinona
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
WO2013012681A1 (en) 2011-07-15 2013-01-24 Abbott Laboratories Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases
US8796289B2 (en) 2011-07-19 2014-08-05 Abbvie Inc. Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases
US9345705B2 (en) * 2011-09-15 2016-05-24 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US9181239B2 (en) 2011-10-20 2015-11-10 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
US9718821B2 (en) 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2015019037A1 (en) 2013-08-05 2015-02-12 Almac Discovery Limited Pharmaceutical compounds
CN104130265B (zh) 2014-04-29 2017-01-25 苏州景泓生物技术有限公司 一种含有螺环或桥环的嘧啶类化合物
JP6487527B2 (ja) 2014-07-04 2019-03-20 チル ファーマシューティカル カンパニー リミテッド スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
CA3003737C (en) * 2015-11-01 2021-09-14 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101432284A (zh) * 2006-04-27 2009-05-13 万有制药株式会社 二氢吡唑并嘧啶酮衍生物
EP2213673A4 (en) * 2007-10-23 2011-09-07 Msd Kk PYRIDONE-SUBSTITUTED DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE
CN105209463A (zh) * 2013-04-11 2015-12-30 阿尔麦克探索有限公司 2-氨基吡啶并[4,3-d]嘧啶-5-酮衍生物及其作为Wee-1抑制剂的用途
CN105829315A (zh) * 2013-12-19 2016-08-03 阿尔麦克探索有限公司 可用作Wee-1激酶抑制剂的嘧啶并嘧啶酮类

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114591334A (zh) * 2020-12-04 2022-06-07 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
CN114591334B (zh) * 2020-12-04 2023-10-20 山东轩竹医药科技有限公司 二氢吡唑并嘧啶酮衍生物
WO2024011883A1 (zh) * 2022-07-13 2024-01-18 江苏天士力帝益药业有限公司 Wee1抑制剂及其制备和用途

Also Published As

Publication number Publication date
EP3572413A4 (en) 2020-08-19
US10954253B2 (en) 2021-03-23
JP2020510630A (ja) 2020-04-09
WO2018133829A1 (zh) 2018-07-26
CN110198943B (zh) 2021-04-16
EP3572413B1 (en) 2021-11-03
US20200017528A1 (en) 2020-01-16
EP3572413A1 (en) 2019-11-27
ES2902050T3 (es) 2022-03-24
JP6717457B2 (ja) 2020-07-01

Similar Documents

Publication Publication Date Title
CN110198943A (zh) 作为Wee1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮衍生物
JP2022505987A (ja) Ｔｙｋ２阻害剤およびその使用
CN109071538A (zh) 作为ask1抑制剂的吡啶衍生物及其制备方法和应用
AU2013213603B2 (en) PDE9 inhibitors with imidazo triazinone backbone
CN108349977A (zh) Jak抑制剂
TW201823249A (zh) Ｍｅｎｉｎ－ｍｌｌ相互作用之稠合二環抑制劑
CN107531711A (zh) Janus激酶抑制剂
CN110418789A (zh) 作为治疗剂的N-环烷基/杂环烷基-4-(咪唑并[1,2-a]吡啶)嘧啶-2-胺的衍生物
CN105228997A (zh) Carm1抑制剂及其用途
TW202216686A (zh) 藉由使ｅｇｆｒ抑制劑與ｅ３連接酶配位體結合來降解（ｅｇｆｒ）以及使用方法
CN109790159A (zh) 抗流感病毒嘧啶衍生物
CA2961607A1 (en) Mk2 inhibitors and uses thereof
CN107531695A (zh) Jak抑制剂
CN107108579A (zh) 作为adamts抑制剂用于治疗骨关节炎的5‑[(哌嗪‑1‑基)‑3‑氧代‑丙基]‑咪唑烷‑2,4‑二酮衍生物
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN110088101A (zh) 一种含氮杂环类化合物、其制备方法、药物组合物及应用
WO2007040166A1 (ja) 新規な縮合ピロール誘導体
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
CN109661395A (zh) Pde4抑制剂
CN110325517A (zh) 螺环类化合物及其应用
CN105085525B (zh) 作为rho激酶抑制剂的异喹啉磺酰衍生物
AU2022202463A1 (en) Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
JP2022523477A (ja) ピロロピリミジン誘導体及びこれを有効成分として含有するタンパク質キナーゼ関連疾患の予防又は治療用薬学的組成物
CA3201540A1 (en) Aromatic heterocyclic compound, pharmaceutical composition and use thereof
EP3160961A2 (en) Small molecule agonists of neurotensin receptor 1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220629

Address after: 214000 room 315, No. 88, Meishan Meiliang Road, Binhu District, Wuxi City, Jiangsu Province

Patentee after: Wuxi Zhikang Hongyi Biotechnology Co.,Ltd.

Address before: 050035 Innovation Building, 315 Changjiang Avenue, Shijiazhuang High-tech Zone, Hebei Province, 3rd Floor

Patentee before: Shijiazhuang Zhikang Hongren New Drug Development Co.,Ltd.